PND62 TREATMENT PATTERNS IN PATIENTS NEWLY DIAGNOSED WITH PARKINSON’S DISEASE

Abstract

We aimed to describe treatment patterns in patients with a new diagnosis of Parkinson’s disease (PD). We identified patients with PD from the IBM MarketScan® Medicare Supplemental and Coordination of Benefits Database. The index date was defined as the first medical claim with a diagnosis of PD using the SNOMED term (49049000) during January 1, 2010 through March 31, 2018. Patients were required to have continuous enrollment in the database at least one year prior to and three years following the index date. Patients were excluded if they had evidence of PD treatment prior to the first observed diagnosis. Treatment patterns were captured during all available follow-up. There were 8,371 newly diagnosed PD patients identified, with an average age of 78 years and 57% were male. Sixty-four percent received at least one PD treatment during follow-up. Of the treated, more than half received exactly one treatment (58%), 42% received ≥2 lines of therapy, while 18% and 6% received ≥3 and ≥4 lines of therapy, respectively. More than three-quarters (79%) of first-line therapy was carbidopa/levodopa, and for 50% of patients carbidopa/levodopa was the only treatment received during follow-up. The average time on first-line therapy was 442 days (±509). Carbidopa/levodopa was also the most common choice for 2nd line therapy (24% of patients who received a 2nd line treatment), followed by rasagline (16%) and ropinirole (14%). Ropinirole (15%), carbidopa/levodopa (14%), and amantadine (13%) were the most common choices for 3rd line therapy. Carbidopa/levodopa is by far the most common treatment option with half of treated patients receiving only that medication. Other therapies appear more often at later lines of therapy, however, only a small proportion of patients receive more than one or two lines of treatment.